Acute myeloid leukemia: 2013 update on risk-stratification and management (Q38092771)

28 August 2017

title

Acute myeloid leukemia: 2013 update on risk-stratification and management (English)

1 reference

28 August 2017

1 reference

acute myeloid leukemia

1 reference

Elihu H Estey

1

1 reference

28 August 2017

publication date

1 April 2013

1 reference

American Journal of Hematology

28 August 2017

published in

1 reference

28 August 2017

volume

88

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

318-327

1 reference

Age and acute myeloid leukemia

28 August 2017

cites work

1 reference

Relapse and death during first remission in acute myeloid leukemia

21 January 2018

1 reference

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

21 January 2018

1 reference

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management

21 January 2018

1 reference

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia

21 January 2018

1 reference

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

21 January 2018

1 reference

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

21 January 2018

1 reference

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

21 January 2018

1 reference

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

21 January 2018

1 reference

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

21 January 2018

1 reference

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia

21 January 2018

1 reference

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

Gemtuzumab ozogamicin: time to resurrect?

21 January 2018

1 reference

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid

21 January 2018

1 reference

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

21 January 2018

1 reference

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

21 January 2018

1 reference

Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

21 January 2018

1 reference

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

Peripheral-blood stem cells versus bone marrow from unrelated donors

21 January 2018

1 reference

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

21 January 2018

1 reference

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

21 January 2018

1 reference

Cytarabine dose for acute myeloid leukemia

21 January 2018

1 reference

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23404

1 reference

28 August 2017

1 reference